Cognitive Outcome in Bipolar Disorder: Current Status and Future Directions for Targeting Treatment

2016 ◽  
Vol 18 ◽  
pp. 46-47
2008 ◽  
Vol 10 (2) ◽  
pp. 129-139 ◽  

Since its "rebirth" in 1966, bipolar disorder (BPD) has rapidly come to occupy a central position in the research and treatment of mood disorders. Compared with major depressive disorder (MDD), BPD is a more serious condition, characterized by much more frequent recurrence, more complex comorbidity, and higher mortality. One major problem is the lack of valid definitions in adult and in child psychiatry; the current definitions are unsatisfactory, and heavily favor an overdiagnosis of MDD. Biological research is partially based on those definitions, which have a short half-life. An additional, dimensional, approach, quantifying hypomania, depression, and anxiety by self-assessment and symptom checklists is recommended. A further, related problem is the early recognition of the onset of BPD, especially in adolescence, and the identification of correlates in childhood. Early and timely diagnosis of BPD is necessary to enable prompt intervention and secondary prevention of the disorder. The paper describes the current status and future directions of developing clinical concepts of bipolarity.


2016 ◽  
Vol 17 (8) ◽  
pp. 755-762 ◽  
Author(s):  
Xu Zhou ◽  
Renhe Liu ◽  
Shuo Qin ◽  
Ruilian Yu ◽  
Yao Fu

2020 ◽  
Vol 11 ◽  
Author(s):  
Nathaniel Edward Bennett Saidu ◽  
Chiara Bonini ◽  
Anne Dickinson ◽  
Magdalena Grce ◽  
Marit Inngjerdingen ◽  
...  

2021 ◽  
Author(s):  
Haoru Dong ◽  
Xinhua Shu ◽  
Qiang Xu ◽  
Chen Zhu ◽  
Andreas M. Kaufmann ◽  
...  

AbstractHuman papillomavirus (HPV) infection identified as a definitive human carcinogen is increasingly being recognized for its role in carcinogenesis of human cancers. Up to 38%–80% of head and neck squamous cell carcinoma (HNSCC) in oropharyngeal location (OPSCC) and nearly all cervical cancers contain the HPV genome which is implicated in causing cancer through its oncoproteins E6 and E7. Given by the biologically distinct HPV-related OPSCC and a more favorable prognosis compared to HPV-negative tumors, clinical trials on de-escalation treatment strategies for these patients have been studied. It is therefore raised the questions for the patient stratification if treatment de-escalation is feasible. Moreover, understanding the crosstalk of HPV-mediated malignancy and immunity with clinical insights from the proportional response rate to immune checkpoint blockade treatments in patients with HNSCC is of importance to substantially improve the treatment efficacy. This review discusses the biology of HPV-related HNSCC as well as successful clinically findings with promising candidates in the pipeline for future directions. With the advent of various sequencing technologies, further biomolecules associated with HPV-related HNSCC progression are currently being identified to be used as potential biomarkers or targets for clinical decisions throughout the continuum of cancer care.


Author(s):  
Minh Tu Nguyen ◽  
Zita Sebesvari ◽  
Maxime Souvignet ◽  
Felix Bachofer ◽  
Andreas Braun ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document